gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 27 May 2015.

Bruton agammaglobulinemia tyrosine kinase

Btk, XLA, Bruton's tyrosine kinase, Xid
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008] (from NCBI)
Top mentioned proteins: BCR, CAN, Syk, Tec, V1a
Papers using Btk antibodies
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
Supplier
von Lindern Marieke et al., In The Journal of Experimental Medicine, 1997
... Rabbit antisera recognizing the mouse EpoR, PLCγ1, Btk, c-Kit, and the antiphosphotyrosine mouse monoclonal antibody PY99 were obtained from Santa Cruz Biotechnology, Inc ...
Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
Supplier
Nürnberg Bernd et al., In The Journal of Cell Biology, 1997
... and BtkPH, restriction sites were introduced by PCR using the indicated primers, the Advantage™ II PCR enzyme system (CLONTECH Laboratories, Inc.) and the ...
The A and the extended V N-terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor alpha in the monocyte cell line THP-1.
Supplier
El Khoury Joseph, In PLoS ONE, 1997
... Anti-Btk mouse IgG monoclonal antibodies were from BD Transduction Laboratories (Le Pont de Claix, France) and anti-TNF-α mouse monoclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany) ...
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Supplier
Nukiwa Toshihiro et al., In Respiratory Research, 1993
... Briefly, mononuclear cells were surface stained with phycoerythrin-labeled anti-CD14 antibody, then fixed, permealized, incubated with anti-BTK monoclonal antibody 48-2H [5] or control IgG1 (Dako, Kyoto, Japan), and then ...
Papers on Btk
Ibrutinib: a new targeted therapy for hematologic cancers.
New
Schneider et al., Durham, United States. In Clin J Oncol Nurs, 01 Jul 2015
BACKGROUND: Hematologic cancers can occur from the overactivity of Bruton's tyrosine kinase, a proto-oncogene in blood cell maturation.
Prolonged and tunable residence time using reversible covalent kinase inhibitors.
New
Taunton et al., San Francisco, United States. In Nat Chem Biol, 25 Jun 2015
Here we made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.
RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.
New
Shi et al., Augusta, United States. In Oncotarget, 12 Jun 2015
However, these large-scale studies only provide information at the transcriptional level.
Emerging treatment options for B-cell lymphomas.
New
Zelenetz, New York City, United States. In J Natl Compr Canc Netw, 31 May 2015
During his presentation at the NCCN 20th Annual Conference, Dr. Andrew D. Zelenetz explored many of them, including the newer immunoconjugates, the Bruton's tyrosine kinase inhibitor ibrutinib, agents targeting apoptosis such as venetoclax (ABT-199), the immunomodulator lenalidomide, and novel immune checkpoint inhibitors such as nivolumab.
Ibrutinib in previously treated Waldenström's macroglobulinemia.
New
Impact
Advani et al., United States. In N Engl J Med, 09 May 2015
MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.
B-cell receptor signaling in diffuse large B-cell lymphoma.
Review
New
Staudt et al., Bethesda, United States. In Semin Hematol, 30 Apr 2015
Pharmacological inhibition with ibrutinib of Bruton's tyrosine kinase, a kinase that is required for BCR signaling to engage NF-κB, is selectively toxic for ABC DLBCL tumors; a finding that has now been translated to the clinic.
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Review
New
Redic et al., Ann Arbor, United States. In J Oncol Pharm Pract, Mar 2015
New therapies currently in the drug development pipeline for relapsed and refractory disease include additional proteasome inhibitors (oprozomib, marizomib, ixazomib), histone deacetylase inhibitors (panobinostat, ricolinostat, quisinostat), monoclonal antibodies (daratumumab, elotuzumab, SAR650984), Bruton's tyrosine kinase inhibitors (ibrutinib), a selective inhibitor of nuclear export, and others.
MicroRNAs in B cell lymphomas: How a complex biology gets more complex.
Review
New
Mraz et al., Brno, Czech Republic. In Leukemia, Jan 2015
We focus on miR-contribution to the regulation of important signalling pathways (like NF-κB, PI3K/AKT, TGF-β), BCR signalling and its modulators (like PTEN, SHIP-1, ZAP-70, GAB1, BTK), anti- and pro-apoptotic proteins (like BCL2, MCL1, TCL1, BIM, p53, SIRT1), and transcription factors (like MYC, MYB, PU.1, FOXP1, BCL6).
Treatment strategies in mantle cell lymphoma.
Review
New
Blum et al., Columbus, United States. In Cancer Treat Res, Dec 2014
Therapy for relapsed disease is dependent on prior treatment, age, comorbidities, and toxicities but includes targeted therapies such as the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, the immunomodulatory agent lenalidomide, the proteasome inhibitor bortezomib, combination chemoimmunotherapy, ASCT, and allogeneic stem cell transplant in selected cases.
Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma.
Review
New
Turturro, Houston, United States. In Biomed Res Int, Dec 2014
Future efforts should aim at targeting the role of NF-κB resistance in clinical trials, where novel agents like lenalidomide and proteasome inhibitors with established activity in this perspective will be an important component in combination therapy, along with new monoclonal antibody, BTK-inhibitors, and other novel therapy agents.
Surface Plasmon Resonance Analysis Shows an IgG-Isotype-Specific Defect in ABO Blood Group Antibody Formation in Patients with Common Variable Immunodeficiency.
New
Wolf et al., Vienna, Austria. In Front Immunol, Dec 2014
RESULTS: When Diamed-ID Micro Typing was used, CVID patients (n = 34) showed IgG- and IgM-isoagglutinins that were comparable to healthy volunteers (n = 28), while all XLA patients (n = 8) had none.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
New
Impact
O'Brien et al., Houston, United States. In Lancet Oncol, Sep 2014
BACKGROUND: Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL).
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
New
Impact
Oki et al., New York City, United States. In Lancet Oncol, Aug 2014
Pharmacodynamic data showed Bruton's tyrosine kinase was fully occupied (>90% occupancy) at the recommended phase 2 dose.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
New
Impact
RESONATE Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Aug 2014
We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
Ibrutinib treatment of CLL: the cancer fights back.
New
Impact
Staudt et al., Bethesda, United States. In Cancer Cell, Aug 2014
Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK).
Tyrosine kinase Btk is required for NK cell activation.
GeneRIF
Cao et al., Shanghai, China. In J Biol Chem, 2012
Data suggest a role of tyrosine kinase Btk in the regulation of immune cell unctions and innate inflammatory response.
Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).
GeneRIF
Nore et al., Huddinge, Sweden. In Mol Cell Biol, 2012
mapped the interaction site to the C terminus of the Btk SH3 domain
Single-chain variable fragment intrabody impairs LPS-induced inflammatory responses by interfering with the interaction between the WASP N-terminal domain and Btk in macrophages.
GeneRIF
Kitani et al., Tsukuba, Japan. In Biochem Biophys Res Commun, 2012
These observations strongly suggest that the phosphorylation of WASP by Btk plays a pivotal role in transducing the LPS signaling pathway in macrophages.
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
GeneRIF
Hendriks et al., Rotterdam, Netherlands. In Blood, 2012
Transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell numbers, leading to antinuclear autoantibody production and systemic lupus erythematosus (SLE)-like autoimmune pathology.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
GeneRIF
Lam et al., Singapore, Singapore. In Proc Natl Acad Sci U S A, 2012
BTK plays a critical role in initiating TLR3 signaling.
share on facebooktweetadd +1mail to friends